Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP).
作者信息
Szántó I, Fleischmann T, Eckhardt S
机构信息
Department of Hematology, National Institute of Oncology, Budapest, Hungary.
出版信息
Oncology. 1991;48(6):456-8. doi: 10.1159/000226980.
PMID:1749581
Abstract
Starting in January 1984, 63 patients with resistant Hodgkin's disease received CEP as salvage-usually third-line-chemotherapy. Complete response (CR) was achieved in 3%, partial response (PR) in 51%. The median duration of remission (CR + PR) was greater than 15 months. Treatment was generally well tolerated. Our results confirm that CEP is an effective therapeutic regimen in resistant Hodgkin's disease.
摘要
Zotero 插件